Request a demo
Ready to explore how evidence-based solutions can support your goals? Book a demo today.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest news

March 24, 2025
/
News

FDA-Cleared Digital Treatments are Shaping the Future of Mental Healthcare

New JAMA Study Showcases Clinical Benefits of SleepioRx in Patients with Comorbid Insomnia and Depression Symptoms, Marking 100+ Peer-Reviewed Papers for Big Health
March 10, 2025
/
News
US FDA Grants Clearance for DaylightRx
September 4, 2024
/
News
US FDA Grants Clearance for SleepioRx
August 8, 2024
/
News
Study Finds Spark Direct Effective in Improving Mood Among Adults With Depression
May 23, 2024
/
News

All News

Evolving Our Leadership At Big Health
August 17, 2022
/
News
First-of-its-kind partnership provides free access to digital mental health treatments for all newly diagnosed cancer patients in the United Kingdom
July 25, 2022
/
News
Sleepio is the first-ever digital therapeutic to receive NICE guidance, confirming clinical and cost effectiveness
May 19, 2022
/
News
First-of-its-Kind Study Demonstrates Digital Therapeutic Significantly Improves Sleep and Mental Health for Stroke Patients
Evaluation shows the value of incorporating Big Health’s Sleepio, a clinically based digital therapeutic for insomnia, into the stroke rehabilitation process
May 4, 2022
/
News
Gabriela Perez Joins Big Health as Chief Commercial Officer
After spending two decades successfully scaling multiple healthcare technology companies, Perez joins Big Health to accelerate the commercial coverage and reimbursement for digital therapeutics
February 3, 2022
/
News
Big Health Adds Former FDA Deputy Commissioner Anand Shah to Its Board of Directors
Dr. Shah joins the Big Health Board of Directors following the company’s Series C funding to expand access to safe and effective mental health care using digital therapeutics
January 26, 2022
/
News
Let's talk
For all media-related queries, please get in touch with us.
Who we are
Learn about our mission, leadership, advisors, and investors.